New Study Identifies GTPase as Novel Target for Fatty Liver Disease Treatment

The Rising Burden of Fatty Liver Disease in Australia

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), has emerged as a major health concern in Australia. Affecting approximately one in three adults, or around 37% of the population, this condition involves excessive fat buildup in the liver cells, often linked to obesity, type 2 diabetes, and metabolic syndrome. 83 90 Projections indicate that by 2030, over 7 million Australians could be impacted, underscoring the urgent need for effective treatments to prevent progression to severe stages like fibrosis, cirrhosis, and liver cancer.

In Australia, where lifestyle factors such as poor diet and sedentary behavior contribute significantly, early intervention is crucial. Universities like the University of Melbourne are at the forefront, contributing liver samples and expertise to international research efforts that promise novel treatment avenues.

A Groundbreaking International Study with Australian Roots

A cutting-edge study published as a reviewed preprint in eLife on December 15, 2025, has pinpointed a novel target for fatty liver disease treatment: genes associated with GTP-binding proteins, or GTPases. 50 101 Titled "Global molecular landscape of early MASLD progression in obesity," the research analyzed liver biopsies from 109 morbidly obese individuals undergoing bariatric surgery in Melbourne hospitals, including The Alfred, Cabrini, and The Avenue.

Led by Philipp Kaldis from Lund University Diabetes Centre in Sweden, with key contributions from Matthew J. Watt, Professor of Anatomy and Physiology at the University of Melbourne, the study integrated transcriptomics and metabolomics. This dual-omics approach revealed distinct molecular signatures separating simple steatosis from fibrosis progression. 121

Key Molecular Insights: From Steatosis to Fibrosis

The research cohort included 33 individuals without MASLD and 76 with early-stage disease, mostly grade 0-1 steatosis and fibrosis. Liver metabolome analysis showed extensive remodeling: elevated glycerolipids like triglycerides (TAGs) and diacylglycerols (DAGs), reduced glycerophospholipids, and dysregulated amino acids such as increased glycine and glutamic acid—precursors for collagen synthesis in fibrosis.

Steatosis correlated with lipid dysregulation and mitochondrial dysfunction, while fibrosis was independently driven by extracellular matrix (ECM) remodeling and hypoxia signaling. Notably, 37 GTPase-related genes were significantly associated with fibrosis, independent of steatosis. 50

Protein network analysis highlighted hubs like ARF3 and RAC1, regulating transport, cytoskeleton dynamics, and exocytosis—processes essential for hepatic stellate cell (HSC) activation and collagen secretion.

GTPases: The Novel Target for Halting Fibrosis Progression

GTPases, small proteins that act as molecular switches by cycling between GTP-bound (active) and GDP-bound (inactive) states, emerged as a promising therapeutic target. Their regulators—guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs)—form a network influencing 508 fibrosis-linked proteins.

In human 3D liver spheroids from MASH patients, 24 GTPase genes were upregulated, partially restored by elafibranor (an existing PPAR agonist). Critically, inhibitors NSC23766 (Rac1) and ML141 (Cdc42) reduced collagen expression and secretion in HSCs, even under TGF-β stimulation—a key fibrosis driver. 121 This suggests GTPase modulation could prevent early fibrosis, a reversible stage where interventions are most effective.

While prior studies hinted at GTPase roles (e.g., Rap1a in steatosis suppression), this is the first human-centric evidence linking them to obesity-driven liver fibrosis, opening doors for drug development.

Australian Contributions: University of Melbourne's Pivotal Role

The study's Australian arm was instrumental, providing high-quality liver biopsies graded by TissuPath pathologists in Victoria. Professor Matthew Watt from the University of Melbourne's School of Biomedical Sciences contributed as corresponding author, leveraging his expertise in lipid metabolism and NAFLD/MASLD. 133

UMelb's involvement aligns with national efforts; the Baker Heart and Diabetes Institute, closely affiliated with Monash University and UMelb, has long researched fatty liver targets. Collaborators like Paul R. Burton from Monash's School of Translational Medicine ensured clinical relevance from Melbourne's bariatric centers.

This highlights Australia's strength in metabolic research, with universities driving global insights into diseases affecting millions locally. Explore research jobs in liver disease at Australian universities to join such impactful work.

Current Landscape of MASLD Treatments and Limitations

• Lifestyle Interventions: Weight loss of 7-10% via diet and exercise remains first-line, resolving steatosis in 50-90% of cases but challenging for adherence.
• Pharmacotherapies: GLP-1 agonists like semaglutide show promise in reducing liver fat; resmetirom (thyroid hormone receptor-β agonist) approved overseas for NASH.
• Gaps: No approved drugs target fibrosis specifically; progression to cirrhosis affects 20-30% of MASLD patients.

The GTPase discovery addresses this gap, potentially complementing existing therapies like elafibranor.Read the full eLife study

Mechanisms of GTPase in Liver Fibrosis: Step-by-Step

1. Activation: TGF-β from inflamed hepatocytes upregulates GTPase genes in HSCs.
2. Switching: GEFs load GTP, activating GTPases like RAC1/Cdc42 for cytoskeleton remodeling.
3. Fibrotic Response: Enhanced exocytosis secretes collagen, forming scar tissue.
4. Inhibition: Specific inhibitors block this cycle, reducing collagen without broad toxicity.

Broader Implications for Australian Public Health

With MASLD linked to 37% of Australians and rising diabetes rates, GTPase-targeted therapies could alleviate healthcare burdens. Early fibrosis intervention might prevent 20% of cirrhosis cases, saving billions in treatment costs.

Australian universities are poised to lead trials; UMelb's metabolic labs offer ideal platforms. Check Australian university jobs for opportunities in this field.

Future Outlook: From Bench to Bedside

Next steps include GTPase inhibitor trials in preclinical models and human organoids. Repurposing existing drugs like NSC23766 could accelerate translation. Australian involvement in global consortia will ensure local applicability.

Optimism surrounds precision medicine for MASLD, with multi-omics guiding personalized treatments.

Actionable Insights for Australians at Risk

• Monitor via FibroScan or blood tests (ELF score).
• Achieve 5-10% weight loss through Mediterranean diet and 150min weekly exercise.
• Consult GPs for metabolic screening; consider clinical trials via Centenary Institute's FAP-index.

For researchers eyeing careers, higher ed career advice and RA jobs abound in liver research.

Conclusion: Hope on the Horizon for Fatty Liver Treatment

This study exemplifies collaborative higher education driving breakthroughs. With UMelb's pivotal role, Australia leads in tackling its fatty liver epidemic. Stay informed and proactive—visit Rate My Professor for insights into top researchers, explore higher ed jobs, and pursue career advice in this vital field.

Photo by David Trinks on Unsplash